Nothing said here yet.
to join the conversation.
| Hansen GwennChief Scientific Officer | Sell | 1,452 | $36.3K | Thu, Oct 15 |
| GREGORY JULIA PDirector | Sell | 22,583 | $528.5K | Wed, Oct 14 |
| Ring ChristineChief Legal Officer | Sell | 5,786 | $134.1K | Fri, Oct 2 |
| Ring ChristineChief Legal Officer | Sell | 5,387 | $138.4K | Wed, Sep 2 |
| Ring ChristineChief Legal Officer | Sell | 400 | $10.7K | Wed, Sep 2 |
| Hansen GwennChief Scientific Officer | Sell | 1,452 | $37.0K | Tue, Sep 1 |
Nurix Therapeutics reported third quarter 2026 revenue of US$673.06 million and net income of US$549.81 million, with both basic and diluted earnings per share from continuing operations turning positive compared with losses a year earlier.
Investing.com -- Nurix Therapeutics Inc (NASDAQ:NRIX) reported third quarter fiscal 2026 financial results on Monday, with revenue of $673.1 million, up significantly from $7.9 million in the same quarter last year.
Nurix Therapeutics (NRIX) delivered earnings and revenue surprises of +944.64% and +383.11%, respectively, for the quarter ended August 2026. Do the numbers hold clues to what lies ahead for the stock?
Nurix Therapeutics, Inc. recently announced that it has extended by two years the research term for an undisclosed oncology program under its ongoing collaboration with Gilead Sciences, originally established in 2019 to develop E3 ligase–based protein…
First patient enrolled in cohort combining bexobrutideg with venetoclax
Two-year extension builds on productive relationship established in 2019
Nurix is developing bexobrutideg in CLL, while Roche's $2.3B deal and new studies support its potential in cancer, immunology and neurology.
Nurix Therapeutics (NRIX) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.